Our present finding that MTH2, MTH3 and NUDT5 expression was associated with CRC progression and the prognosis, suggested that these proteins, in addition to MTH1, may be potential therapeutic targets for CRC. The gene discussed is NUDT5; the disease is colorectal carcinoma.